Synthetic peptides were selectively bound to the leucine-rich α-2-glycoprotein 1 (LRG1) that was overexpressed in CRC patients, and the level of plasma LRG1 was related to the progression of CRC from the adenoma stage to carcinoma [146]. Here, LRG1 is linked to carcinoma.